New figures from the BioIndustry Association (BIA) show that UK biotech companies secured £2.11 billion in equity financing between April and June 2026, including a record £2.05 billion in venture capital.

After several years in which access to capital has remained one of the sector’s biggest challenges, the figures provide a significant indication that investor confidence is beginning to return.

But behind the headline number is a more complicated – and potentially more important – story about where investment is flowing and what that could mean for the next generation of UK life sciences companies.

A Landmark Quarter for UK Biotech

The second quarter of 2026 delivered the strongest quarterly venture capital total recorded by UK biotech in five years.

A substantial proportion came from one company. London-based Isomorphic Labs, the AI-driven drug discovery company spun out of Google DeepMind, completed a $2.1 billion Series B financing round, valued at approximately £1.6 billion in the BIA figures.

The scale of the investment reflects the extraordinary interest surrounding the convergence of artificial intelligence and drug discovery, with Isomorphic Labs developing AI systems designed to accelerate the identification and development of new medicines.

The round inevitably transformed the headline figures for the quarter. But removing it does not remove the wider recovery.

The Recovery Goes Beyond One Megadeal

Excluding Isomorphic Labs, UK biotech companies still raised £498 million in venture capital during the quarter.

That compares with £279 million during the same period in 2025.

More importantly, investment is beginning to appear across different stages of company growth.

Eight seed deals were completed during the quarter, with an average value of £6.4 million. Series A companies collectively raised around £190 million, while later-stage Series B+ companies secured approximately £225 million.

There has also been movement in the crucial £10 million to £25 million funding range. Twice as many companies raised rounds of this size during the first half of 2026 as did across the entirety of 2025.

For the UK life sciences ecosystem, this matters.

Large financing rounds attract attention, but a sustainable biotech sector also depends on companies being able to access capital as they move from early research into clinical development, commercialisation and scale-up.

The UK Leads Europe for Biotech Investment

The figures also reinforce the UK’s position within the European biotech market.

UK companies attracted 61% of the £3.3 billion in venture capital invested across European biotech during the second quarter of 2026.

That places the UK firmly at the centre of European biotech investment at a time when countries across the continent are competing to attract scientific talent, companies and international capital.

The strength of the UK ecosystem has traditionally been associated with established clusters around London, Oxford and Cambridge. But successful life sciences companies increasingly emerge from a much broader national network of universities, hospitals, laboratories, manufacturers and innovation organisations.

Regional ecosystems, including the West Midlands, form an important part of that pipeline, particularly across diagnostics, medical technology, advanced manufacturing, healthcare innovation and university spinouts.

For the UK to maintain its position, the challenge is not simply producing promising science. It is creating the conditions for companies to remain, grow and raise substantial capital in the UK.

Public Markets Remain the Missing Piece
Despite the strength of private investment, the recovery is far from complete.

Public markets remain notably subdued.

Follow-on financing for listed UK biotech companies reached £58 million during the second quarter, up from £36 million in Q1 and £15 million during the same quarter last year.

Yet no UK biotech IPOs have taken place so far in 2026.

That creates an important divide within the market. Private investors are showing renewed willingness to back promising companies, but the public financing environment has yet to experience the same recovery.

For growing biotech businesses, that matters because venture capital cannot support every stage of development indefinitely. A healthy ecosystem ultimately requires multiple routes to capital, from seed investment and venture funding through to institutional finance, public markets, partnerships and acquisitions.

What Comes Next?

The second quarter does not mean the difficult funding environment facing biotech has disappeared.

Investment remains selective, public markets remain weak and raising capital continues to be challenging for many companies.

But the direction of travel is encouraging.

The significance of the latest figures is not simply that one exceptional company raised an exceptional amount of money. It is that underneath that deal, investment activity is beginning to broaden across different stages of the UK biotech ecosystem.

For founders, investors and researchers, the question now is whether that momentum can be sustained.

It is a particularly timely question ahead of Life Sciences Week 2026, taking place from 21–25 September. Funding, investment, commercialisation and scale-up will form part of the wider conversation as researchers, businesses, investors, healthcare leaders and policymakers come together across Birmingham, the West Midlands and beyond.

After years in which the UK life sciences funding debate has often focused on what is missing, the latest figures provide something different: evidence that capital is beginning to move again.

The challenge now is turning one strong quarter into sustained growth.

Sources: BioIndustry Association, UK biotech financing April–June 2026; Isomorphic Labs.